Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Collins DM, Madden SF, Gaynor N, AlSultan D, Le Gal M, Eustace AJ, Gately KA, Hughes C, Davies AM, Mahgoub T, Ballot J, Toomey S, O'Connor DP, Gallagher WM, Holmes FA, Espina V, Liotta L, Hennessy BT, O'Byrne KJ, Hasmann M, Bossenmaier B, O'Donovan N, Crown J. Collins DM, et al. Among authors: madden sf. Clin Cancer Res. 2021 Feb 1;27(3):807-818. doi: 10.1158/1078-0432.CCR-20-2007. Epub 2020 Oct 29. Clin Cancer Res. 2021. PMID: 33122343 Free PMC article. Clinical Trial.
The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.
Eustace AJ, Madden SF, Fay J, Collins DM, Kay EW, Sheehan KM, Furney S, Moran B, Fagan A, Morris PG, Teiserskiene A, Hill AD, Grogan L, Walshe JM, Breathnach O, Power C, Duke D, Egan K, Gallagher WM, O'Donovan N, Crown J, Toomey S, Hennessy BT. Eustace AJ, et al. Among authors: madden sf. Breast Cancer Res Treat. 2021 Jun;187(3):635-645. doi: 10.1007/s10549-021-06244-1. Epub 2021 May 13. Breast Cancer Res Treat. 2021. PMID: 33983492 Free PMC article.
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT. Toomey S, et al. Among authors: madden sf. Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9. Breast Cancer Res. 2017. PMID: 28750640 Free PMC article. Clinical Trial.
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J. Eustace AJ, et al. Among authors: madden sf. BMC Cancer. 2018 Oct 11;18(1):965. doi: 10.1186/s12885-018-4852-1. BMC Cancer. 2018. PMID: 30305055 Free PMC article.
BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.
Walsh L, Haley KE, Moran B, Mooney B, Tarrant F, Madden SF, Di Grande A, Fan Y, Das S, Rueda OM, Dowling CM, Varešlija D, Chin SF, Linn S, Young LS, Jirström K, Crown JP, Bernards R, Caldas C, Gallagher WM, O'Connor DP, Ní Chonghaile T. Walsh L, et al. Among authors: madden sf. Clin Cancer Res. 2019 Dec 1;25(23):7139-7150. doi: 10.1158/1078-0432.CCR-19-0713. Epub 2019 Aug 13. Clin Cancer Res. 2019. PMID: 31409615
107 results